$94.89
0.70%
Nasdaq, Nov 17, 01:21 pm EST. Market open.
ISIN
BMG5269C1010
Symbol
KNSA

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$94.23
+15.64 19.90% 1M
+40.59 75.67% 6M
+52.98 128.44% YTD
+52.83 127.61% 1Y
+78.73 507.94% 3Y
+81.35 631.60% 5Y
+74.76 383.98% 10Y
+74.76 383.98% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-2.10 2.18%
ISIN
BMG5269C1010
Symbol
KNSA
Industry

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$7.4b
Enterprise Value
$6.8b
Net debt
positive
Cash
$568.8m
Shares outstanding
78.5m
Valuation
P/E
71.9
P/S | estimate
7.8 | 6.9
EV/Sales | estimate
7.2 | 6.4
EV/FCF | ex SBC
34.7 | 44.9
P/B
10.4
Financial Health
Equity Ratio
74.3%
Return on Equity
10.4%
ROCE
16.5%
ROIC
25.1%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$45.0m | 4.8%
SBC as % of FCF
22.8%
SBC Growth 1Y
28.3%
Share Count Growth 1Y
4.1%
Shareholder Yield
-4.1%
Financials
Revenue | estimate
$946.0m | $1.1b
EBITDA
$132.4m
EBIT
$130.5m
Net Income
$109.6m
Free Cash Flow | ex SBC
$197.2m | $152.2m
Growth
Revenue | estimate
58.2% | 58.1%
EBITDA
233.9%
EBIT
241.9%
Net Income
205.0%
Free Cash Flow
93.9%
Margin
Gross
90.2%
EBITDA
14.0%
EBIT
13.8%
Net
11.6%
Free Cash Flow | ex SBC
20.9% | 16.1%
More
EPS
$1.3
FCF per Share
$2.5
Short interest
10.6%
Employees
366
Rev per Employee
$1.9m

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
92%
Hold
8%

Kiniksa Pharmaceuticals Ltd. Class A Events

Past Events
OCT
27
Q3 2026 Earnings Call
21 days ago
JUL
28
Q2 2026 Earnings Call
4 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
APR
28
Q1 2026 Earnings Call
7 months ago
FEB
24
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
OCT
28
Q3 2025 Earnings Call
about one year ago

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Sep '26
+/-
%
946 946
58% 58%
100%
- Direct Costs 93 93
25% 25%
10%
853 853
63% 63%
90%
- Selling and Administrative Expenses 247 247
37% 37%
26%
- Research and Development Expense 136 136
39% 39%
14%
132 132
234% 234%
14%
- Depreciation and Amortization 1.90 1.90
28% 28%
0%
EBIT (Operating Income) EBIT 130 130
242% 242%
14%
Net Profit 110 110
205% 205%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Neutral
GlobeNewsWire
●
21 days ago
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, p...
Positive
Investors Business Daily
●
2 months ago
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Mr. Patel
Employees 366
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today